Form 4: Amgen EVP David M. Reese Reports Stock Transaction
SEC Filing
David M. Reese, EVP & Chief Technology Officer of Amgen, reports the disposition of 690 shares of common stock to cover tax obligations related to vesting restricted stock units.
Summary
- On April 30, 2024, David M. Reese, EVP & Chief Technology Officer of Amgen, filed a Form 4 with the SEC.
- The report details the disposition of 690 shares of Amgen common stock at a price of $276.38.
- This transaction was related to the satisfaction of tax obligations arising from the vesting of Restricted Stock Units (RSUs).
- Following the transaction, Reese beneficially owns 59,976 shares of Amgen common stock, including unvested RSUs and dividend equivalents.
Sentiment
Score: 5
Explanation: This is a routine disclosure of a stock transaction related to vesting equity, and does not indicate a particularly positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine sale of shares to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 04/30/2024 | Date of stock transaction and filing of Form 4 |
| 05/05/2024 | Vesting date for 1,180 RSUs |
| 04/30/2025 | Vesting date for 1,363 RSUs |
| 05/02/2024 | Vesting date for 1,286 RSUs |
| 05/02/2025 | Vesting date for 1,286 RSUs |
| 05/02/2026 | Vesting date for 1,325 RSUs |
| 05/02/2025 | Vesting date for 1,258 RSUs |
| 05/02/2026 | Vesting date for 1,259 RSUs |
| 05/02/2027 | Vesting date for 1,297 RSUs |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.